Abstract:Objective To study the prognostic factors of survival in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib.Methods From May 2008 to Dec 2012,the clinical data of 82 cases with mRCC adminstered by sunitinib were reviewed retrospectively.The study included 60 male patients and 22 female patients,whose age ranged from 29 to 82 years [mean (56.1±11.3) years].Among them,52 cases presented hematuria,flank pain and palpable mass.The size of renal tumor ranged from 2.0 to 18.0 cm [mean (8.0±3.0) cm].The location of tumor included 41 in left kidney,37 in right kidney and 4 in bilateral kidney.The pathological tissue obtained from the operation in 69 cases and from biopsy in 13 cases.The pathological results demonstrated renal cell carcinoma in 75 cases,papillary cell carcinoma in 2 cases,chromophobe cell carcinoma in 2 cases,sarcomatoid carcinoma in 2 cases,collecting duct carcinoma in one case.The site of metastasis included lung in 50 cases,liver in 11 cases,bone in 14 cases,pancrease in 3 cases,retroperitoneal lymph node in 31 cases.In 52 cases,the ECOG scores ranged from 1 to 2.The others scores were more than 3.The average level of hemoglobin,AKP,LDH and leukocyte were (132±24)g/L,(90±65) U/L,(168±114) U/L and (6.4±2.0)×109/L,respectively.Before treatment,the abnormal cases in those parameters were 59,9,6 and 2,respectively.According to the MSKCC risk model,14 cases were classified into the high risk group and 68 cases into medium risk group.74 cases were accepted the sunitinb therapy within one year after diagnosis and 8 cases were accepted same therapy until one year after diagnosis.The overall survival (OS) rates were calculated by Kaplan-Meier method and Cox regression model was used to analyze the relationship between the influencing factors and the prognosis.Results The average OS was (21.6± 14.1) months (ranged 2.8 to 64.1 months).The survival rate at 1 st,2nd and 3rd year were 71％,64％ and 58％,respectively.Single factor analysis showed that significant prognostic factors were as follows:ECOG performance status ≥ 2 (P =0.005),clinical symptom during first clinic visiting (P =0.031),without nephrectomy (P =0.012),the number of metastatic sites ≥ 2 (P =0.015),hemoglobin before treatment (P=0.005),serum AKP level before treatment (＞126 U/L) (P=0.007),MSKCC score≥ 3 (P =0.000),the presence of liver metastases (P =0.000) and bone metastases (P =0.000) and relative dose intensity in the first month (1M-RDI) of sunitinib ≥ 50％ (P=0.000).Cox regression model showed that the beneficial predictive factors were ECOG performance status＜2 (P=0.136),no symptom during the first clinic visiting (P=0.801),serum AKP ＜126 U/L (P=0.618) before treatment,the absence of bone (P =0.068) and pancreas metastases (P =0.265).Sunitinib 1M-RDI ≥ 50％ was the independent predictive factor (P=0.000).Conclusions In targeted therapy era,there is some change in the prognostic factors for mRCC and target drug play an important role in the prognosis of mRCC.Sunitinib 1M-RDI ≥50％ is the independent predictive factor for the prognosis of renal carcinoma.

Hand-Foot Syndrome (hfs) and Asthenia/Fatigue (A/F) As Biomarkers of Sunitinib Efficacy in Chinese Patients (pts) with Metastatic Renal Cell Carcinoma (Mrcc).

Early Presence of Antiangiogenesis-Related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Patients with Metastatic Gastric Cancer Treated with Apatinib.

Baseline Radiologic Features As Predictors of Efficacy in Patients with Pancreatic Neuroendocrine Tumors with Liver Metastases Receiving Surufatinib.

High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy.

Evaluation of Hypertension and Hand-Foot Syndrome As Markers of Anlotinib Efficacy in Advanced Soft Tissue Sarcoma.

Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study.

Efficacy and Safety of First-Line Sunitinib in Chinese Patients with Metastatic Renal Cell Carcinoma

Hand-foot Skin Reaction is a Beneficial Indicator of Sorafenib Therapy for Patients with Hepatocellular Carcinoma: a Systemic Review and Meta-Analysis

Clinical Outcomes of Patients with or Without Common AEs in Anlotinib Cohort: Subgroup Analysis of the ALTER0303 Trial.

Prognostic Factors for Overall Survival with Targeted Therapy in Chinese Patients with Metastatic Renal Cell Carcinoma.

[Exploratory Analysis of the Effect of Toxicity of Sunitinib on the Clinical Outcome of Patients with Advanced Renal Cell Carcinoma].

Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers.

A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS)

Prognostic Factors of Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib

Comparison of Efficacy, Safety, and Quality of Life Between Sorafenib and Sunitinib As First-Line Therapy for Chinese Patients with Metastatic Renal Cell Carcinoma

[Efficacy and the Multivariate Analysis of Sunitinib As First-Line Treatment in Patients with Metastatic Renal Cell Carcinoma].

The Evaluation of Efficacy and Safety of Sunitinib on EGFR‐TKI Pretreated Advanced Non‐small Cell Lung Cancer Patients in China

Hand-foot-skin Reaction of Grade ≥ 2 Within Sixty Days As the Optimal Clinical Marker Best Help Predict Survival in Sorafenib Therapy for HCC

Association of Single Nucleotide Polymorphisms in Agt, Vegf, and Apoe Genes with Clinical Outcome of Target Therapy in Advanced Renal Cell Carcinoma

[Comparison of Efficacy Between Sorafenib and Sunitinib As First-Line Therapy for Metastatic Renal Cell Carcinoma and Analyze Prognostic Factors for Survival].

Clinical Efficacy and Tolerance of Sunitinib in the Treatment of Advanced Renal Cell Carcinoma